Funding for this research was provided by:
Canadian Institutes of Health Research (201410PHE-PHE- 337814–96399)
Fonds de Recherche du Québec - Santé (2016/2017–33087)
Article History
Received: 16 November 2018
Accepted: 10 June 2019
First Online: 9 July 2019
Ethics approval and consent to participate
: The trial protocol was approved by the Research Ethics Board of the Centre de Recherche de l’Institut Universitaire de Gériatrie de Montréal, Canada, as part of the Centre Intégré Universitaire en Santé et Services Sociaux du Centre-Sud de l’île de Montréal, Canada on 20 July 2017 (CER VN 17–18-25) (ClinicalTrials.gov identifier: NCT03400384). Consent to conduct this policy evaluation was provided by the Executive Director of the Provincial Drug Programs Branch, the Health Information Privacy Committee of Manitoba Health, Seniors and Active Living (MHSAL) and the Manitoba Monitored Drugs Review Committee. The trial was endorsed by the College of Physicians and Surgeons of Manitoba. Neither patient informed consent nor physician informed consent are required since both physician and patient information will be obtained in accordance with provincial privacy legislation and approved by a provincial information access committee.
: The Provincial Drug Programs Branch within the Manitoba Health, Seniors and Active Living Department of the Government of Manitoba has agreed to publish the results of the trial as a scientific manuscript and conference presentations. Approval was also granted by the Health Information Privacy Committee in accordance with provincial privacy legislation.
: The authors declare that they have no competing interests.